BenevolentAI

BenevolentAI, founded in 2013 and headquartered in London, UK, operates at the intersection of AI, Big Data, Biotechnology, Pharmaceutical, and Machine Learning. The company's mission, encapsulated in its slogan, "Technology in service of life," is to enhance and protect human quality of life through advanced technological solutions.

The company gained recognition when its AI system identified baricitinib as a potential treatment for Covid-19 within 48 hours, showcasing its ability to extend scientific capacity rather than replace it. Today, BenevolentAI offers Qor, a strategic decision intelligence platform aimed at revolutionizing the biotech landscape.

With its last reported investment of $90.00M in a Private Equity Round from Temasek Holdings in September 2019, BenevolentAI is well-positioned to leverage its innovative approach within the life sciences sector. The startup's focus on enabling the ecosystem through AI-driven insights highlights its strategic value to potential investors.